retatrutide phase 2 nejm 2023 obesity trial results Achieves Large Weight Decreases in Patients Without Diabetes: TRIUMPH-1 Retatrutide Dosing Guide: 1-12 mg

10.1016/S2213-8587(18)30024-X 42

In a notice viewed by STAT, HCA said use of the GLP-1 weight loss drugs surged 90% this year, significantly raising costs

GLP-1 is a promising target for the treatment of depression because impaired neurogenesis ability and the reduction of neuronal differentiation leads to multiple depressive pathological symptoms

However, high doses ( 0.5 mg/kg/d) may activate the SREBP-1c pathway, increase liver fat synthesis, and lead to hypertriglyceridemia and fatty liver

Chitosan-based oral nanoparticles as an efficient platform for kidney-targeted drug delivery in the treatment of renal fibrosis